Clinical Trials
Acetylon Pharma starts treating patients in Phase 1-2a multiple myeloma drug trial
Acetylon Pharmaceuticals has started treating patients in a three-part Phase 1-2a trial to evaluate ACY-1215 in adult patients suffering from relapsed and relapsed/refractory multiple myeloma. The Phase 1 dose-ranging study expects to investigate ACY-1215...
Clinical Trials
Neurocrine starts tardive dyskinesia drug Phase II trial
US based Neurocrine Biosciences has started a second double-blind, placebo controlled, randomized cross-over Phase II trial to evaluate NBI- 98854. The company is developing NBI-98854 to address the unmet medical needs of patients suffering...
Clinical Trials
Bionor Pharma to initiate HIV Vacc-4x combination trial
Bionor Pharma is set to initiate a double blinded, randomized and placebo-controlled trial to evaluate HIV-vaccine candidate Vacc-4x in combination with Revlimid.Revlimid is indicated as a treatment for multiple myeloma and anemia due to myelodysplastic syndrome linked with a...
Clinical Trials
Scancell updates on cancer vaccine Phase I clinical trial
The Cohort Review Committee has approved Scancell to further escalate cancer vaccine SCIB1 dose to 4mg from the current 2mg in the Phase I clinical trial and recruitment of the final group of patients as planned. ...
Clinical Trials
Aeras, OETC commence TB drug Phase IIb trial
Aeras and the Oxford-Emergent Tuberculosis Consortium (OETC) have commenced a Phase IIb trial to investigate a new experimental tuberculosis vaccine in TB patients with human immunodeficiency virus (HIV) infection. The trial will evaluate the HIV patients...
Clinical Trials
Alnylam concludes liver cancer drug Phase I trial
US based drug developer Alnylam Pharmaceuticals has concluded an open label, multi-center, dose escalation Phase I trial evaluating ALN-VSP as a treatment for advanced solid tumors with liver involvement. ALN-VSP is a systemically delivered RNAi therapeutic...
Clinical Trials
Sinapis Pharma concludes Phase I stroke drug trial
Sinapis Pharma has concluded first Phase I clinical trial of oral and IV administration of methamphetamine HCl for the treatment of stroke and traumatic brain injury. The single-center, open-label, randomized, two-period, two-treatment, two-sequence, single dose, crossover...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read